Medshine Discovery Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to an androgen receptor targeting moiety via a linker acting as androgen receptor degradation inducers reported to be useful for the treatment of cancer.
Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical (Shanghai) Ltd. have synthesized antibody-drug conjugates consisting of an antibody covalently linked to exatecan derivatives through a linker.
Shaanxi Panlong Pharmaceutical Group Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) targeting moiety via linker acting as 3CLpro (SARS-CoV-2) degradation inducers reported to be useful for the treatment of SARS-CoV-2 infection.
Tencent Technology (Shenzhen) Co. Ltd. has disclosed pyrrolo[2,1-f][1,2,4]triazine derivatives acting as dual specificity protein kinase TTK inhibitors reported to be useful for the treatment of cancer.
Metacen Therapeutics Corp. has synthesized compounds able to capture methylglyoxal (MGO) reported to be useful for the treatment of aging, diabetes, hyperlipidemia, neurodegeneration, autism spectrum disorder, nonalcoholic fatty liver disease (NAFLD), fibrosis and cardiovascular disorders.
Johns Hopkins University has described prodrugs of sphingomyelin phosphodiesterase 3 (SMPD3; nSMase2) inhibitors reported to be useful for the treatment of cancer, neurological disorders, infections and inflammatory disorders.
RSS